Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
84.8M
-
Shares change
-
-3.56M
-
Total reported value, excl. options
-
$783M
-
Value change
-
-$36.5M
-
Put/Call ratio
-
0.11
-
Number of buys
-
82
-
Number of sells
-
-84
-
Price
-
$9.24
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2025
199 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.8M shares
.
Largest 10 shareholders include FMR LLC (8.89M shares), BlackRock, Inc. (6.76M shares), Deep Track Capital, LP (6.06M shares), VANGUARD GROUP INC (4.49M shares), BAKER BROS. ADVISORS LP (3.88M shares), Commodore Capital LP (3.78M shares), Redmile Group, LLC (3.68M shares), Vestal Point Capital, LP (3.48M shares), Point72 Asset Management, L.P. (2.87M shares), and STATE STREET CORP (2.86M shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.